Drugs / NKT2152
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05119335 | Oct 2021 → Aug 2025 | clear cell renal carcinoma | NiKang Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04524871 | Nov 2020 → Jul 2027 expected | liver cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05935748 | Jul 2023 → Jun 2025 | clear cell renal carcinoma | NiKang Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-07-20 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | HANSOH PHARMA ANNOUNCED STRATEGIC COLLABORATION WITH NIKANG THERAPEUTICS FOR EXCLUSIVE RIGHTS TO NKT2152 IN CHINA hspharm.com ↗ |
| 2022-01-05 | AVEO Pharmaceuticals, Inc. | NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2α Inhibitor, and FOTIVDA® (tivozanib) for the Treatment of Advanced Clear Cell Renal Cell Carcinoma aveooncology.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKT2152 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04524871 ↗ |
| Action | Inhibit | “Oral HIF2α inhibitor” NCT05119335 ↗ |
| Route | Oral | “NKT2152 will be administered by mouth.” NCT04524871 ↗ |